{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C+Virus+Genotype-1&page=2", "query": { "condition": "Hepatitis C Virus Genotype-1", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 206, "total_pages": 21, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C+Virus+Genotype-1&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C+Virus+Genotype-1&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T01:56:32.923Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02114151", "title": "Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "Simeprevir", "type": "DRUG" }, { "name": "Sofosbuvir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Infectious Diseases BVBA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 103, "start_date": "2014-04", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-04-04", "last_synced_at": "2026-10-04T01:56:32.923Z", "location_count": 32, "location_summary": "Dothan, Alabama • Bakersfield, California • Chula Vista, California + 29 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02114151" }, { "nct_id": "NCT01500772", "title": "Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Alisporivir", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 6, "start_date": "2012-03", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2016-08-01", "last_synced_at": "2026-10-04T01:56:32.923Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01500772" }, { "nct_id": "NCT00743795", "title": "Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HCV Infection" ], "interventions": [ { "name": "placebo", "type": "DRUG" }, { "name": "GS-9190", "type": "DRUG" }, { "name": "Peginterferon Alfa 2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 252, "start_date": "2008-10", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2013-11-05", "last_synced_at": "2026-10-04T01:56:32.923Z", "location_count": 48, "location_summary": "Anaheim, California • Los Angeles, California • Newport Beach, California + 37 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Clemente", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00743795" }, { "nct_id": "NCT02349048", "title": "Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Simeprevir 150 mg", "type": "DRUG" }, { "name": "Daclatasvir 60 mg", "type": "DRUG" }, { "name": "Sofosbuvir 400 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 68, "start_date": "2015-01", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2017-03-01", "last_synced_at": "2026-10-04T01:56:32.923Z", "location_count": 7, "location_summary": "Bakersfield, California • Jacksonville, Florida • Lutherville, Maryland + 4 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Lutherville", "state": "Maryland" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02349048" }, { "nct_id": "NCT01446250", "title": "Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Alisporivir", "type": "DRUG" }, { "name": "Boceprevir", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 8, "start_date": "2011-12", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2017-01-16", "last_synced_at": "2026-10-04T01:56:32.923Z", "location_count": 2, "location_summary": "Beverly Hills, California • Baltimore, Maryland", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01446250" }, { "nct_id": "NCT00663208", "title": "A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 167, "start_date": "2008-05", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2015-10-14", "last_synced_at": "2026-10-04T01:56:32.923Z", "location_count": 7, "location_summary": "Anaheim, California • Cypress, California • New Haven, Connecticut + 4 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Cypress", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00663208" }, { "nct_id": "NCT01331850", "title": "A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" }, { "name": "RO5024048", "type": "DRUG" }, { "name": "danoprevir", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 381, "start_date": "2011-05", "completion_date": "2013-01", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-04T01:56:32.923Z", "location_count": 19, "location_summary": "La Jolla, California • Long Beach, California • Sacramento, California + 15 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01331850" }, { "nct_id": "NCT00606086", "title": "Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Genotype 1 Chronic Hepatitis C" ], "interventions": [ { "name": "GI-5005", "type": "DRUG" }, { "name": "Pegylated Interferon and Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlobeImmune", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2007-12", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2014-06-27", "last_synced_at": "2026-10-04T01:56:32.923Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00606086" }, { "nct_id": "NCT01415141", "title": "Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "telaprevir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Vermont", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2011-07", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-10-04T01:56:32.923Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Burlington, Vermont", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT01415141" }, { "nct_id": "NCT00517439", "title": "A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" }, { "name": "RO4588161", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 516, "start_date": "2007-12", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-04T01:56:32.923Z", "location_count": 30, "location_summary": "Phoenix, Arizona • La Jolla, California • Long Beach, California + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00517439" } ] }